Riverain Technologies Issued a U.S. Patent for Vessel Suppression Technology
June 13 2018 - 10:17AM
Business Wire
Riverain Technologies, an industry leader and innovator in
proprietary image analysis and machine learning technologies,
announced today that the United States Patent and Trademark Office
(USPTO) has awarded the company a broad patent for its technology
that forms a vessel suppressed, chest CT series using deep learning
and synthetic data modeling. The patent holds enormous promise for
improving the detection and diagnosis of lung cancer at an earlier
stage while making clinicians more efficient, a first for computer
aided detection.
Riverain has been issued U.S. Patent
9,990,743 for its methodology to selectively remove
anatomical structures from CT scans to optimize reading accuracy
and efficiency for lung cancer detection. The technology is used in
the company’s premier software, ClearRead CT™. ClearRead CT is
proven to lead to more accurate and efficient detection of lung
nodules, the early indicator of lung cancer. A range of possible
applications exists within other imaging modalities including MRI,
positron emission tomography (PET), full field digital mammography
and tomosynthesis, where normal structures interfere with the
detection and diagnosis of disease.
Riverain Technologies
Riverain Technologies is a clinical AI software innovator that
develops solutions to aid clinicians in the early detection of
disease. For more information visit:
http://www.riveraintech.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180613005731/en/
Riverain TechnologiesKelley Wright,
937-531-5088kwright@riveraintech.com